期刊
TRENDS IN MOLECULAR MEDICINE
卷 14, 期 4, 页码 161-168出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2008.01.003
关键词
-
Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor P-cell function in patients with type-2 diabetes mellitus. However, at supraphysiollogical doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic P cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiollogical basis the clinical use of these therapeutics is reviewed here.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据